DEA Transcript Moves Federal Cannabis Rescheduling Toward Recommendation
Legal team analyzing cannabis rescheduling record
Federal cannabis rescheduling has entered another important decision stage. DEA has published the corrected transcript from 11 days of administrative hearings held between June 29 and July 15, 2026. The complete record runs 2,533 pages and captures arguments over whether cannabis should move from Schedule I to Schedule III. With testimony finished and final written arguments submitted, Chief Administrative Law Judge Derek Julius can now prepare his recommended decision.
Quick facts
• DEA published transcripts covering all 11 days of the federal cannabis rescheduling hearing
• The complete hearing transcript runs 2,533 pages
• Hearings took place from June 29 through July 15, 2026
• The evidentiary record closed after testimony concluded on July 15
• Participating parties had until August 17 to submit post hearing briefs and proposed transcript corrections
• Judge Julius ordered final transcript corrections before the complete record was released publicly
• DEA argued that cannabis no longer meets the requirements for Schedule I because it has a currently accepted medical use in the United States
• Opponents challenged the federal medical use analysis, safety findings, worker testing implications, and other aspects of the proposed move
• Judge Julius will issue a recommended decision after reviewing the complete record
• Participating parties can raise exceptions to the recommendation before the DEA Administrator considers the matter
• The DEA Administrator ultimately makes the final agency determination in this proceeding
• The universal operator lesson is simple: a major federal decision may be getting closer, but businesses should continue operating under rules that are actually effective rather than assuming a future outcome
If federal rescheduling is affecting your tax, financing, medical cannabis, or expansion strategy, complete our quick Puro Risk intake form so you can map compliance, insurance, operational, and financial exposure before a federal decision changes your assumptions.
Why the transcript matters
The transcript gives operators, attorneys, investors, researchers, and policymakers access to the complete evidentiary record the judge will evaluate.
That matters because the rescheduling debate has moved beyond headlines and political statements.
The record contains testimony addressing accepted medical use, relative safety, abuse potential, scientific evidence, worker safety, drug testing, and the legal standards used to determine scheduling.
DEA defended the proposed move to Schedule III and argued that federal evidence supports a currently accepted medical use. Opposing parties challenged both the evidence and the analytical framework supporting the proposed change.
The judge now has to weigh those competing arguments.
Why the recommendation is not the final decision
The next major development is the recommended decision from Judge Julius.
At the close of the hearing, Julius made clear that his recommendation will not be the final agency decision. Participating parties will have an opportunity to file exceptions to his recommendation before the matter reaches the DEA Administrator.
That distinction is important for operators.
A favorable recommendation would be meaningful, but businesses should not treat it as the same thing as a final rule or effective scheduling change.
Why 280E remains a major planning issue
Federal tax treatment remains one of the largest financial consequences associated with broader rescheduling.
Section 280E restricts ordinary federal tax deductions for businesses trafficking in Schedule I or Schedule II controlled substances. Broader Schedule III treatment could therefore materially alter the economics of qualifying cannabis activity.
The federal picture is already more complicated than it was a year ago. Since April 28, 2026, qualifying state licensed medical cannabis and certain FDA approved cannabis products have separate Schedule III treatment under a federal final rule.
The broader administrative proceeding addresses cannabis outside that existing medical framework.
Operators should therefore avoid treating medical and adult use activity as though they currently have identical federal status.
Why operators should prepare for several outcomes
Rescheduling could affect taxes, capital markets, research, DEA registration, medical strategy, compliance systems, and investor confidence.
It could also face additional procedural or legal challenges.
That means businesses need scenario planning rather than one forecast built around Schedule III arriving on a specific date.
If federal policy is influencing capital or operational decisions, complete the Puro Risk intake form to organize licensing, contracts, insurance, compliance, financing, and other exposures before the next federal milestone.
Conclusion
The release of the full 2,533 page hearing transcript moves federal cannabis rescheduling deeper into the decision process.
The testimony is complete. Post hearing briefs have been filed. The official record has been corrected and released. Judge Julius can now evaluate the evidence and prepare his recommendation.
But the process is not finished.
The recommendation can be challenged by participating parties, and the DEA Administrator ultimately controls the final agency determination.
For operators, investors, lenders, and medical cannabis companies, the strongest strategy remains preparation. Understand which business decisions depend on federal reform, model multiple outcomes, maintain clean compliance records, and avoid spending anticipated tax savings before the applicable rules actually change.
Educational note: This article is for education only and is not legal, regulatory, tax, financial, medical, investment, DEA registration, accounting, research, employment, or insurance advice.
What to do this week
• Separate current federal requirements from assumptions based on broader Schedule III treatment
• Model financial performance under current tax treatment and potential future 280E relief
• Review whether medical and adult use operations currently receive different federal treatment
• Identify financing, investment, or expansion decisions that depend on rescheduling
• Organize licensing, compliance, tax, insurance, and DEA related records
• Track the recommended decision without treating it as final agency action
FAQ
How long is the DEA cannabis rescheduling hearing transcript?
The complete transcript covers 11 hearing days and runs 2,533 pages.
When did the hearings take place?
The formal evidentiary hearings ran from June 29 through July 15, 2026.
What happens next?
Chief Administrative Law Judge Derek Julius will review the hearing record and issue a recommended decision on broader cannabis rescheduling.
Does the judge make the final decision?
No. Participating parties can raise exceptions to the recommendation, and the DEA Administrator ultimately issues the final agency determination.
Would broader Schedule III treatment affect 280E?
A broader move from Schedule I to Schedule III could materially change how Section 280E applies to qualifying cannabis activity, although actual tax treatment depends on the final rules, effective dates, and individual business circumstances.
What is the biggest operator takeaway?
The federal process is moving closer to a decision, but operators should continue planning around multiple outcomes until final agency action actually occurs.
Compliance team reviewing cannabis rescheduling documents
You might also like
SOURCES
Marijuana Moment, DEA Releases Full Cannabis Rescheduling Hearing Transcript As Judge Prepares Recommendation, August 25, 2026
Marijuana Moment reports that the corrected transcript runs 2,533 pages across 11 hearing days and summarizes the major arguments presented by DEA and opposing parties.
Drug Enforcement Administration, Proposed Rescheduling Hearing Transcripts And Orders
DEA publishes all 11 corrected hearing transcripts along with the orders governing transcript corrections and post hearing briefs. The final hearing transcript confirms that the judge's recommendation is not the final decision and that the DEA Administrator will ultimately issue the agency determination.
Federal Register, Schedule III Treatment For Qualifying Medical Cannabis, April 28, 2026
The federal final rule confirms that qualifying state licensed medical cannabis and certain FDA approved cannabis products have already received Schedule III treatment while the broader rescheduling proceeding continues.
DEA has released the complete 2,533 page transcript from 11 days of federal cannabis rescheduling hearings as the administrative law judge prepares a recommendation. The record moves the process closer to a decision while operators continue facing uncertainty around 280E, federal compliance, medical cannabis strategy, research, and investment timing.